Overview

A Clinical Study of [177Lu]Lu-XT117 Injection in Patients With Advanced Solid Tumors

Status:
Recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
This is a single-center, single-arm clinical study to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [177Lu]Lu-XT117 injection in patients with FAP-positive advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Xinlu Wang
Collaborator:
Sinotau Pharmaceutical Group